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ABSTRACT 
 
Background: Various studies have shown association of much physical and psychosocial comorbidity with 
psoriasis. Aims & Objectives: To note pattern of various comorbidities in psoriasis patients and the association of 
systemic comorbidities with severity of psoriasis. Materials & methods: Cross sectional study of 200 psoriasis 
patients was done.Detailed history and examination done. Investigations included complete blood count, CRP, ESR, 
urine routine and microscopic examination, LFT, RFT, S .calcium, lipid profile, blood sugar estimation, S. protein, 
TFT, ultrasound abdomen. In case of joint involvement- X-ray of involved joint, Rheumatoid factor and S. uric acid 
were done. General Health Questionnaire 12 for psychiatric morbidity, CASPAR criteria for psoriatic arthritis, ATP 
III criteria for metabolic syndrome, cardiovascular criteria based on BMI , NCEP for lipid levels, AGA diagnostic 
criteria for non-alcoholic fatty liver disease, were used for calculation. Statistical analysis was done by Chi-Square 
Test. Results: most common comorbidities noted were:- abdominal obesity (71%), increased BMI (70%), 
dyslipidemia (40%); hypertension (28%); diabetes mellitus (25%); metabolic syndrome (21.5%); Increased 
cardiovascular risk (81.5% based on BMI; 71% based on waist circumference) was noted. Significant association 
between disease severity and increased BMI, psoriatic arthritis, psychiatric comorbidity was noted. Conclusion: 
Screening of all patients for comorbidities and prompt treatment is necessary to break the vicious cycle of 
comorbidities worsening psoriasis and vice-versa, as well as for therapeutic implications. 
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Introduction 
 
 
Psoriasis, an immune-mediated skin disease, has 
various systemic and cutaneous comorbidities, as 
shown by previous studies. These comorbidities are 
found to be more in patients with moderate to severe 
psoriatic skin disease [1].Some of the concomitant 
medications for comorbidities may worsen psoriasis; 
conversely, systemic treatment of psoriasis with certain 
drugs may impact the comorbid conditions. This 
necessitates a multidisciplinary approach, with  
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coordination between dermatologists and other 
specialists, to minimize co-medication and 
morbidity[2].Thus, it is necessary for a dermatologist 
to be aware of comorbidities prevalent in psoriasis 
patients and the significance of timely screening. 
However, there are only few Indian studies on the 
various comorbidities prevalent in psoriasis and there 
are no recommended guidelines for screening in Indian 
population. 
 
Materials and methods 
An observational, prospective, cross-sectional study of 
200 patients of psoriasis with comorbidities, aged 
above 18 years, attending outpatient department of 
PDU Government Medical College & Hospital, Rajkot 
was done over a period of 2 years, from November 
2013 to October 2015.With informed consent, 
detailed history was taken including duration of the 
disease, joint pain, smoking, alcohol intake, tobacco 
 
Asian Pac. J. Health Sci., 2017; 4(1):27-33                                     e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Kulkarni et al     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2017; 4(1):27-33 
www.apjhs.com      28 
 
consumption, concomitant illnesses, concomitant drug 
intake and family history of psoriasis. Thorough 
clinical examination was done and the severity of 
disease was calculated by psoriasis area severity index 
(PASI) score, presence of nail, or joint involvement. 
Biometric data such as weight, height, waist 
circumference were noted. Waist circumference was 
measured at the highest level of the iliac crest[3]]. 
Investigations included complete blood count 
(hemoglobin, total count, differential count, platelet 
count), C reactive protein, erythrocyte sedimentation 
rate, urine routine and microscopic examination, liver 
function tests, renal function tests, serum total protein 
and albumin, serum calcium, lipid profile, blood sugar 
estimation, thyroid function tests, ultrasound abdomen.. 
In clinically difficult cases, biopsy was done for 
diagnosis. Specific investigations included: 
electrocardiogram (ECG) in  patients with history of 
cardiovascular risk factors; chest X ray and pulmonary 
function tests with history of respiratory complaints 
and referred to physician if abnormal; X-ray of 
involved joint, Rheumatoid factor, and S. uric acid with 
history of joint pains[4].The statistical analysis was 
done by Chi-Square Test. 
Various scores and criteria used for the study are as 
follows: 
1) PASI calculation[5]: Four sites of affection, the head 
(h), upper limbs (u), trunk (t) and lower limbs (l), were 
scored by using three parameters: erythema (E), 
infiltration (I) and desquamation (D), each of which 
was graded on a severity scale of 0-4, where 0 = nil, 1 
= mild, 2 = moderate, 3 = severe and 4 = very severe. 
      The area-wise percentage involvement of the 
involved sites was calculated as: 1 ≤ 10% area; 2 = 
10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; and 6 
= more than 90%. 
      The final formula for PASI score: PASI = 0.1 (Eh + 
Ih + Dh) Ah + 0.2 (Eu + Iu + Du) Au + 0.3 (Et + It + 
Dt) At + 0.4 (El + Il + Dl) A1 
      Mild psoriasis was classified as a PASI between 0 
and 7, moderate between 8 and 12 and severe>12.
3
 
 2) Body mass index (BMI) was calculated using the 
formula: Weight (kg) /Height (m
2
). According to 
Indian guidelines, a BMI from 23 to 24.9 is 
overweight, ≥ 25 is moderate obesity, and ≥ 30 is 
severe obesity. Cut-off values for waist circumference 
for Indian men and women were 90cm and 80 cm, 
respectively[3]. 
 3) Cardiovascular risk was estimated based on BMI 
(as recommended by WHO Expert Consultation Group 
in Asian population[6] 
4) Metabolic syndrome (MS) can be identified by 
presence of three or more of the Adult Panel III (ATP 
III) criteria[3]. 
1. Elevated waist circumference - Men: ≥90 cm; 
Women: ≥80 cm ( for Asians) 
2. Reduced HDL- Men: <40 mg/dl; Women: <50 
mg/dl 
3. Elevated blood pressure- ≥130/85 mm Hg 
4. Elevated fasting glucose- ≥100 mg/dl 
5. Elevated triglycerides- ≥150 mg/dl 
5) The diagxnosis of psoriatic arthritis (PsA) was based 
on the classification criteria  of psoriatic arthritis 
(CASPAR) criteria[4]. Number of tender and/or 
swollen joints were counted and the pattern of arthritis 
was recorded according to Moll and Wright’s 
classification criteria. Spondylitis was diagnosed when 
at least one of the following was present in a patient 
with inflammatory back pain, with or without 
peripheral joint disease/ Tenderness on the spine or 
sacroiliac joint / sacroiliitis on pelvis X-ray / spinal 
syndesmophytes on X-ray[4]. 
6) The National Cholesterol Education Program Blood 
Lipid guidelines for optimal blood lipid levels were 
used[3].
 
7) GENERAL HEALTH QUESTIONNAIRE -12 (for 
General Psychiatric Morbidity) was used to detect 
psychiatric morbidity- SCORE ≥ 2 is considered 
significant[7]. 
8) NAFLD (non-alcoholic fatty liver disease) 
diagnostic criteria: (as per American Association for 
the Study of Liver Diseases, American College of 
Gastroenterology, and the Amerivcan 
Gastroenterological Association 2012)[8]. 
 
Table 1: Cardiovascular risk was estimated based on BMI (as recommended by WHO Expert Consultation 
Group in Asian population) 
 
 
 
 
BMI Risk 
18.5—23 kg/m2 Acceptable risk 
23—27.5 kg/m2   Increased risk 
>27.5 kg/m2 High risk 
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Results 
Various systemic comorbidities observed in our study 
are as in [Table 2].Cardiovascular risk was increased in 
81.5% cases based on BMI and in 71% cases based on 
increased waist circumference. Most of the patients 
44% cases had long duration of disease (>5yrs). No 
significant association was found between Metabolic 
Syndrome and duration of the disease. Maximum 
patients (77.5%) had mild disease (PASI <8). No 
association was found between MS, its components 
(individually) and severity of the disease [Table 3]. 
Amongst patients with respiratory comorbidity (5 
cases),2 cases of chronic obstructive pulmonary disease 
(COPD) and 1 case of bronchial asthma had history of 
smoking. Of the 11 patients with thyroid disorder, 4 
cases were previously known hyperthyroids and 5 
cases were already known hypothyroids on treatment. 
All of them had mild psoriasis (PASI<8) except two 
hypothyroid cases having severe disease (PASI-15 and 
13.5).Of the 4% cases with alcohol addiction, 1.5% 
cases had fatty liver. Fatty liver (with no history of 
alcoholism) was observed in 4.5% cases [0.5% case 
was on oral methotrexate treatment and 4% cases had 
NAFLD]. Amongst patients with NAFLD, 2 patients 
had hypertension and 1 case had MS. One case (0.5%) 
of each renal stones (without any associated 
nephropathy) and chronic renal failure were noted. The 
patient with chronic renal failure also had diabetes 
mellitus (DM), hypertension (HTN), diabetic 
retinopathy and diabetic neuropathy.1 out of 2 cases 
with human immunodeficiency virus (HIV) infection in 
our study with PASI-6 had crusted lesions [figure 1] 
whose diagnosis was confirmed by biopsy. Recurrent 
exacerbations of psoriasis were seen in patient of 
Down syndrome with the age of onset at 29 years, less 
compared to the mean age of onset seen in females i.e., 
47.48%.Psoriatic arthritis was seen in 6% cases and 
asymmetrical oligoarthritis was the most common 
pattern observed [figure 2 & 3].Amongst systemic 
comorbidities associated, we found significant 
association between severity of the disease and 
increased BMI, psoriatic arthritis, psychiatric 
comorbidity; while no significant association with rest 
of the comorbidities [Table 4].Various associated 
cutaneous disorders (infectious and non-infectious) 
noted are in our study are Tinea unguium(1.5%), 
Intertrigo(0.5%), Pitted keratolysis(0.5%), Tinea 
corporis(1.5%),  verruca vugaris(2%), Herpes 
labialis(0.5%), Pityriasis versicolor(0.5%), Phototoxic 
reaction, Vitiligo(1.5%), Acute urticaria, LSEA, 
Seborrheic keratoses,  Dermatosis papulosa nigra,  
Bullous pemphigoid, Acne(1%), Xanthelesma(1%). 
 
Discussion 
A recent meta-analysis indicates elevated risk of 
cardiovascular events in psoriatic patients in relation to 
non-psoriatic controls [9]. Also, Asian-Indians have a 
higher predisposition to obesity, metabolic syndrome, 
diabetes, and cardiovascular disorders as compared to 
western populations.
 
Psychological comorbidity in 
psoriasis leads to addiction to alcohol, smoking and 
tobacco chewing. Both alcohol and smoking in turn 
worsen psoriasis. Also alcohol intake releases 
proinflammatory cytokines like TNF-alpha, 
exacerbating psoriasis and causing alcoholic 
hepatitis[10].In our study, HTN, abdominal obesity and 
ischemic heart disease (IHD) were more common 
while DM, family history of DM, alcohol addiction and 
tobacco chewing were more common in Periera et al 
study[6].The increased cardiovascular risk due to 
increased BMI as well as due to increased waist 
circumference, in our study was comparable to Periera 
et al study findings[6].Abdominal obesity prevalence 
varies across different populations. Love TJ et al [11] 
found that, abdominal obesity was most common 
component of metabolic syndrome associated with 
psoriasis followed by hypertriglyceridemia and low 
levels of HDL cholesterol.
 
Abdominal obesity was 
more in males contradicting the findings of Love TJ et 
al which was probably due to higher male: female ratio 
in our study.
 
Several studies have shown that psoriasis 
is associated with atherogenic  dyslipidemia. The 
association with dyslipidemia was less in our study 
compared to Pierera  et al[6].MS is a strong predictor 
of cardiovascular disease, that confers a cardiovascular 
risk higher than the individual components[5].
 
We 
found no significant relationship between the duration 
of the disease and the presence of MS similar to 
findings in study by Madanagobalane S et al[3].In 
present study, PASI score ranged from 0.2 to 34.6 with 
mean and median of 4.8 and 1.5, respectively. While, 
in study by Madanagobalane S et al[3], PASI score 
ranged from 0.6 to 45.6 with mean and median of 6.2 
and 82. Maximum number of patients (77.5% cases) 
who presented to our OPD had mild disease (PASI <8). 
Out of 45 (22.5%) patients, who had moderate and 
severe psoriasis, 6 patients had MS. We found no 
significant association between MS and extent of 
involvement as well as between the severity of the 
disease and various components of MS, against the 
findings of Madagobalane S et al[3].The presence of 
psychological distress in our study group (11%) was 
comparable to that in group of Kumar et al 
(16%)[12].Around 79% patients with severe psoriasis 
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have negative impact on their lives. Competition, 
increased cosmetic awareness and the stresses of day-
to-day life make psoriasis patients feel inferior and less 
competent as compared to the normal population, 
which leads to anxiety and depression, which get 
further precipitated by the frequent relapses and 
chronicity of the disease[12].Psoriasis in HIV is known 
to have increased exacerbations, increased association 
with PsA and may present with atypical lesions like 
papules, crusted and hyperkeratotic lesions[13]. 
Unstable psoriasis associated with Down’s syndrome 
has been reported by our study comparable to Mariyath 
et al[14].Many studies have shown increased 
association of COPD with psoriasis. Since both 
psoriasis and bronchial asthma are chronic immune-
mediated inflammatory diseases, increased prevalence 
of asthma with psoriasis has been seen[15].Moderate to 
severe psoriasis is also a risk factor for chronic kidney 
disease (CKD). There is nearly a two-fold risk of 
moderate to advanced CKD among psoriasis patients 
and a greater than four-fold risk of end stage renal 
disease, independent of other comorbidities. The risk of 
CKD associated psoriasis is greater than the risk of 
CKD associated with diabetes and hypertension.The 
cause for CRF in our patient could not be ascertained 
to particular cause as the patient also had HTN and DM 
with microvascular complications. Thyroid hormones 
increase EGF and may cause uncontrolled and 
relapsing psoriasis[16].
 
Arican et al found the serum 
TT4 and FT3 levels were significantly higher in 
psoriatics than in the control group and also they had 
higher PASI scores .But we did not find severe disease 
with hyperthyroidism, probably as they were under 
treatment.
 
NAFLD, considered as hepatic manifestation 
of the metabolic syndrome, is associated with risk of 
cardiovascular disease and methotrexate-induced 
hepatotoxicity.  In an Indian study, the occurrence of 
NAFLD was higher in psoriasis patients than in 
controls[17]. NAFLD patients in the psoriasis group 
were more likely to have metabolic syndrome and 
diabetes than those with psoriasis alone, which was not 
seen in our study. 6% cases had PsA comparable with 
Indian prevalence of 1-9%. Variations with findings 
from Kumar et al[4] study were probably due to 
smaller sample size of PsA (n=12) in our study. 
Significant association was not found between disease 
severity and increased BMI; psoriatic arthritis and 
psychiatric comorbidity only probably because 77.5% 
(i.e., more than ¾ th) of the sample belonged to mild 
psoriasis group. 
Cutaneous comorbidities: Xanthelesma usually 
represents a localized cutaneous phenomenon, but may 
signify a systemic hyperlipidemia, as seen in one of our 
case. Seborrheic keratosis can be a cutaneous marker of 
internal malignancy, though in our case it was not 
eruptive seborrheic keratosis. Various studies have 
shown increased association of psoriasis with 
malignancy including cutaneous tumors and solid 
organ tumors. Hence according to AHA 
recommendations, age appropriate screening for 
various malignancies is necessary in all patients. 
Itching associated with LSEA, urticaria and eczema 
can aggravate psoriasis due to koebnerisation and 
reduce the efficacy of treatment.  Amongst the 
cutaneous autoimmune conditions, various studies have 
shown association of vitiligo [figure 4] and bullous 
pemphigoid with psoriasis, though the strength of 
association is not known yet. 
Conclusion 
The above findings of various comorbidities associated 
with psoriasis indicate that a dermatologist should 
always screen for the coexistent comorbidities as the 
management of psoriasis depends on comorbidities and 
vice-versa. Till the screening guidelines are available, 
the dermatologist has to rely upon relevant history, 
clinical examination and investigations, for the 
detection of comorbidities at the earliest. Paucity in 
Indian data regarding the subject needs to be addressed 
by conducting more epidemiological studies with 
larger sample size, which will help in formulating 
screening guidelines for Indian population.  
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Fig 1: Psoariasis presenting as crusted 
papules in HIV Infection 
Fig 2: Arthritis mutilans 
 
Fig 3: X Ray(AP view both hands)multiple 
deformities noted involving pip, dip, mcp jts 
Fig 4: Psoriatic plaques on vitiligo patches 
 
Table 2: Distribution of patients based on various co- morbidities observed in our study 
Systemic comorbidity Present study % (n=200) 
Metabolic syndrome 21.5 
HTN 28 
DM 25 
IHD 5 
Dyslipidemia 40 
Morbid obesity 25 
Obesity 36.5 
Overweight 8.5 
Hyperthyroidism 2.5 
Hypothyroidism 3 
COPD, Bronchial asthma 2.5 
Psychiatric comorbidity 11 
Alcohol dependence 4 
Chronic renal failure, renal stones 1 
Down’s syndrome 0.5 
Psoriatic arthropathy 6 
HIV 1 
Tuberculosis 0 
Fatty liver/ cirrhosis liver* 1.5 
 
Asian Pac. J. Health Sci., 2017; 4(1):27-33                                     e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Kulkarni et al     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2017; 4(1):27-33 
www.apjhs.com      32 
 
*H/O chronic alcoholism present 
**NAFLD: non-alcoholic fatty liver disease 
Table 3: Relation between disease severity and metabolic syndrome, its components 
Metabolic syndrome and 
its 
components 
 
Present study (2015)% (n=200) Madanagobalane S et al
3
  (2012)% (n=118) 
PASI 
>12 
Severe 
 
PASI 
8–12 
Mod-
erate 
 
PASI 
<8 
Mild 
 
P 
value 
 
PASI 
>12 
Severe 
PASI 
8–12 
Mod-
erate 
 
PASI 
<8 
Mild 
 
P 
value 
 
Metabolic syndrome 5 1 37 0.138 8 6 38 0.499 
Waist circumference 
≥90 cm (M) or 
≥80 cm (F) 
17 16 109 0.449 3 7 37 0.018 
Triglyceridemia ≥150 
mg/dl 
4 5 29 0.977 
 
7 4 30 0.043 
HDL <40 mg/dl (M) or 
<50 mg/dl (F) 
3 1 27 0.352 10 12 54 0.176 
Blood pressure ≥130/85 
mmHg 
6 7 45 0.980 2 8 26 0.018 
Fasting plasma glucose 
≥100 mg/dl 
6 6 45 0.955 9 9 54 1.000 
 
 
Table 4: Relation between disease severity and various systemic comorbidities 
 
systemic comorbidity present study (2015) no. (n=200) 
PASI >12 
severe 
PASI 8–12 
moderate 
 
PASI 
<8 
mild 
 
P 
value 
 
DM 4 6 40 0.95 
HTN 3 6 47 0.484 
IHD 1 1 8 0.85 
Dyslipidemia 6 9 65 0.712 
Increased BMI 18 21 101 0.038 
Psychiatric comorbidity 6 4 12 0.027 
Psoriatic arthritis 5 0 7 0.004 
NAFLD 2 1 5 0.612 
COPD 0 0 3 0.908 
Bronchial asthma 1 1 0 0.49 
Hyperthyroidism 0 0 5 0.93 
Hypothyroidism 2 0 4 0.287 
 
 
 
 
 
 
 
NAFLD ** 4 
Ca breast 0.5 
Hepatitis B 0.5 
 
Asian Pac. J. Health Sci., 2017; 4(1):27-33                                     e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Kulkarni et al     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2017; 4(1):27-33 
www.apjhs.com      33 
 
References 
 
1.  Onumah N, Kircik LH. Psoriasis and its 
comorbidities. J Drugs Dermatol. 2012 May;11(5 
Suppl):5-10. 
2. Aurangabadkar SJ. Comorbidities in psoriasis. 
Indian J Dermatol Venereol Leprol 2013;79:10-7 
3. Madanagobalane S, Anandan S. Prevalence of 
metabolic syndrome in south Indian patients with 
psoriasis vulgaris and the relation between 
disease severity and metabolic syndrome: A 
hospital-based case-control study. Indian J 
Dermatol 2012;57:353-7 
4. Kumar R, Sharma A, Dogra S. Prevalence and 
clinical patterns of psoriatic arthritis in Indian 
patients with psoriasis. Indian J Dermatol 
Venereol Leprol 2014;80:15-23. 
5.  Lakshmi S, Nath AK, Udayashankar C. 
Metabolic syndrome in patients with psoriasis: A 
comparative study. Indian Dermatol Online J 
2014;5:132-7. 
6. Pereira RR, Amladi ST, Varthakavi PK. A study 
of the prevalence of diabetes, insulin resistance, 
lipid abnormalities, and cardiovascular risk 
factors in patients with chronic plaque psoriasis. 
Indian J Dermatol 2011;56:520-6 
7.  Kremers HM, McEvoy MT, Dann FJ, Gabriel 
SE. Heart disease in psoriasis. J Am Acad 
Dermatol. 2007 ;57(2):347-54. 
8.  Chalasani et al. the diagnosis and management of 
non-alcoholic fatty liver disease: practice 
guideline by the American Association for the 
Study of Liver Diseases, American College of 
Gastroenterology, and the American 
Gastroenterological Association. Am J 
Gastroenterol 2012; 107:811-829 
9. Pietrzak et al. Cardiovascular aspects of psoriasis: 
an updated review. International Journal of 
Dermatology.2013;52(2): 153–162 
10. Cassano N, Vestita M, Apruzzi D, Vena GA. 
Alcohol, psoriasis, liver disease, and anti-
psoriasis drugs.Int J Dermatol. 2011 
;50(11):1323-31. 
11. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, 
Choi HK. Prevalence of the metabolic syndrome 
in psoriasis: Results from the National Health and 
Nutrition Examination Survey, 2003-2006. Arch 
Dermatol 2011;147:419-24 
12.  Kumar S, Kachhawha D, Koolwal GD, Gehlot S, 
Awasthi A. Psychiatric morbidity in psoriasis 
patients: A pilot study. Indian J Dermatol 
Venereol Leprol 2011;77:625 
13. Alexander E, Pinto J, Pal GS, Kamath N, 
Kuruvilla M. Disease concomitance in psoriasis: 
A clinical study of 61 cases. Indian J Dermatol 
Venereol Leprol 2001;67:66-8 
14.  Mariyath O R, Pinto J. Unstable psoriasis in 
down’s syndrome. Indian J Dermatol Venereol 
Leprol 2003;69, Suppl S1:61-3 
15. Kumar S, Nayak CS, Padhi T, Rao G, Rao A, 
Sharma V K, Srinivas C R. Epidemiological 
pattern of psoriasis, vitiligo and atopic dermatitis 
in India: Hospital-based point prevalence. Indian 
Dermatol Online J 2014;5, Suppl S1:6-8 
16. Arican O, Bilgic K, Koc K. The effect of thyroid 
hormones in psoriasis vulgaris. Indian J Dermatol 
Venereol Leprol 2004;70:353-6 
17. P Gisondi et al, Non-alcoholic fatty liver disease 
in patients with chronic plaque psoriasis, J 
Hepatol. 2009 ;51(4):758-64. 
18. Madanagobalane S, Anandan S.The increased 
prevalence of non-alcoholic fatty liver disease in 
psoriatic patients: a study from South India. 
Australas J Dermatol. 2012;53(3):190-7. 
 
 
Source of Support: Nil                                     
Conflict of Interest: None  
 
